Tag: board

LIVERMORE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Inertia Enterprises, the commercial fusion energy company, today announced the formation of its Science and Technology Advisory Board (STAB). The newly formed advisory board is an independent group of the world's foremost experts in fusion plasma physics, high-energy laser systems, large-scale program execution, target fabrication, and nuclear materials science. Its purpose is to provide rigorous, independent technical assessment across Inertia's physics, target, laser, and power plant development programs as the company prepares to deliver grid-scale fusion energy in the 2030s.

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace’s comprehensive suite of technologies for its growing customer base

Creates a scaled BDC positioned for growth while maintaining industry leading credit quality and portfolio yield

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

Bank of Åland Plc
Stock Exchange Release
June 18, 2026, 9.00 EEST

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.